An Appraisal Of The Status Of Chagas Disease In The United States

This title critically reviews old and new literature, help to create greater awareness of the disease in the US and helps in the evaluation of certain epidemiological and public health issues. During the first half of the 20th century, Chagas disease was assumed to be absent from the U.S. and considered an exotic disease, until the first two indigenous cases were discovered, almost simultaneously, in Texas, 1955. Since that time four indigenous cases have been documented in several places in the country. Although the disease is still considered uncommon in the US, this disease is not longer an exclusive Latin American illness. Physicians in the US are often unaware of the characteristics of the diseases, and are likely overlooking locally acquired cases. The influx of an estimated 300,000 Latin American immigrants with the Chagas parasite means that there is an urgent need for physicians and public health officials to become aware. Helps to create greater awareness of Chagas disease in the USA Helps to evaluate epidemiological and public health issues Facilitates accurate and necessary future public health interventions

This title critically reviews old and new literature, help to create greater awareness of the disease in the US and helps in the evaluation of certain epidemiological and public health issues. During the first half of the 20th century, Chagas disease was assumed to be absent from the U.S. and considered an exotic disease, until the first two indigenous cases were discovered, almost simultaneously, in Texas, 1955. Since that time four indigenous cases have been documented in several places in the country. Although the disease is still considered uncommon in the US, this disease is not longer an exclusive Latin American illness. Physicians in the US are often unaware of the characteristics of the diseases, and are likely overlooking locally acquired cases. The influx of an estimated 300,000 Latin American immigrants with the Chagas parasite means that there is an urgent need for physicians and public health officials to become aware. Helps to create greater awareness of Chagas disease in the USA Helps to evaluate epidemiological and public health issues Facilitates accurate and necessary future public health interventions

Chagas disease causes severe socioeconomic impact and a high medical cost in Latin America. WHO and the World Bank consider Chagas disease as the fourth most transmittable disease to have a major impact on public health in Latin America: 120 million persons are potentially exposed, 16 to 18 million of whom are presently infected, causing 45,000 to 50,000 deaths per year. It has been calculated that approximately 2.4 million potential working years are lost because of incapacity and mortality due to the disease, for an annual cost estimated at 20 billion Euros. American Trypanosomiasis provides a comprehensive overview of Chagas disease and discusses the latest discoveries concerning the three elements that compose the transmission chain of the disease: The host: human and mammalian reservoirs The insect vectors: domestic and sylvatic vectors The causative parasite: Trypanosoma cruzi Informs and updates on all the latest developments in the field Contributions from leading authorities and industry experts

This report of a WHO Expert Committee reviews current knowledge of Chagas disease and its pathogenesis discusses the causative parasite the triatomine vectors and the natural reservoirs of infection and considers the epidemiology and incidence trends of the disease. Prevention and control strategies are described as are the various formal initiatives for interruption of disease transmission. The report concludes by identifying priorities for research and offering guidance for the planning implementation and strengthening of national control programmes. ... this book makes an extremely valuable contribution toward understanding Chagas disease and promoting solid prevention and control efforts. It will no doubt be an important addition to the library of anyone student and expert alike with interests in Chagas disease. The authors are to be congratulated on the completion of a work of excellence - an extremely difficult endeavour at a time when our knowledge of vectors parasites and methodologies is expanding so rapidly. - Transactions of the Royal Society of Tropical Medicine and Hygiene

The Disease Reference Group on Chagas Disease Human AfricanTrypanosomiasis and Leishmaniasis (DRG3) was part of an independent thinktankof international experts established by the Special Programme for Researchand Training in Tropical Diseases (TDR) to identify key research prioritiesthrough systematic review of research evidence and input from stakeholders. These three distinct insect-borne diseases while caused by related kinetoplastidprotozoan pathogens have dissimilar geographical distributions a reflection oftheir different insect vectors and range of vector contact with humans. Thedisease.

"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.

Chagas disease is a potentially life threatening condition that was historically mainly endemic to Latin America. Over the last decade, however, the disease has spread to and is increasingly prevalent in other continents such as North America and Europe, with an estimated 7 million people infected worldwide. It is primarily transmitted by insect vectors that carry the parasite Trypanosoma cruzi, the disease agent. In areas where there is vector control and in non-endemic countries, it is mainly transmitted via congenital infection. Cardiac and gastrointestinal complications are common in untreated individuals. This book offers a comprehensive overview of Chagas disease, including its vectorial and congenital transmission, and molecular diagnosis, which is essential for screening, and developing and providing timely, effective anti-trypanosomal treatment. Written by experts working with infected patients on a daily basis, it discusses the pathogenesis of congenital, cardiac, gastrointestinal and oral Chagas disease, as well as its treatment and the pharmacological aspects of drug development in this area. Chapter "Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities" is available open access under a via link.springer.com.